<DOC>
	<DOCNO>NCT02159040</DOCNO>
	<brief_summary>The primary objective study compare overall response rate ( inclusive complete response , partial response hematologic improvement ) per IWG 2006 criterion patient high risk MDS treat azacitidine without deferasirox achieve course one year . Hematologic improvement must maintain least 8 week .</brief_summary>
	<brief_title>Phase II Study Evaluate Overall Response Patients With Higher Risk Myelodysplastic Syndromes ( MDS ) Treated With Azacitidine With Without Deferasirox .</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Male Female , age ≥ 18 year Patients high risk MDS blast count &lt; 20 % time screen IPSS Int2 High Risk Serum Ferritin ≥ 300 ng/mL screening . Sexually active woman must use effective method contraception , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal ( define amenorrhea least 12 month ) Patients currently receive therapy AZA MDS ( ≥ 4 week washout period agent ( exclude AZA ) use treat MDS prior first dose study treatment require ) . Patients receive &gt; 2 cycle AZA decitabine time randomization . Patients receive iron chelation therapy within 1 month screening . Patients receive growth factor within 1 month screening . Patients receive Revlimid within 1 month screening . Patients undergone hematopoietic stem cell transplant . ECOG Performance Status &gt; 2 Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent study treatment Patients uncontrolled systemic hypertension Severe cardiac insufficiency ( NYHA III IV ) , uncontrolled and/or unstable cardiac coronary artery disease control standard medical therapy Patients diagnosis history clinically relevant ocular toxicity relate iron chelation Diagnosis liver cirrhosis ( either establish diagnosis diagnosis liver biopsy central ultrasound read ) Clinical laboratory evidence active Hepatitis B Hepatitis C ( HBsAg absence HBsAb OR HCV Ab positive HCV RNA positive ALT normal range ) . History HIV positive test result ( ELISA Western blot ) Presence surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug Patients active malignancy ( currently within past two year ) exception basal cell skin carcinoma cervical carcinoma situ completely resect colonic polyp carcinoma situ . History drug alcohol abuse within 12 month prior enrollment . History noncompliance medical regimen patient consider potentially unreliable and/or cooperative . Patients know hypersensitivity azacitidine , mannitol , deferasirox . Calculated creatinine clearance &lt; 40mL/min Serum creatinine great 1.5x ULN screen Urine protein/creatinine ratio &gt; 1 AST ALT great 3x ULN screen Direct Bilirubin great 1.5x ULN screening . Patients receive treatment systemic investigational drug within past 4 week topical investigational drug within past 7 day plan receive investigational drug participate study Patients participate another therapeutic clinical trial Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment . Sexually active male unless use condom intercourse take drug 3 month stop AZA father child period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Int-2 MDS</keyword>
</DOC>